Details of the Drug Combination

General Information of Drug Combination (ID: DCY7GDV)

Drug Combination Name
Terameprocol Aminolevulinic Acid Hydrochloride
Indication
Disease Entry Status REF
Minimally invasive lung adenocarcinoma Investigative [1]
Component Drugs Terameprocol   DMC3P45 Aminolevulinic Acid Hydrochloride   DMWNHPC
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: NCI-H322M
Zero Interaction Potency (ZIP) Score: 0.57
Bliss Independence Score: 3.59
Loewe Additivity Score: 1.8
LHighest Single Agent (HSA) Score: 1.59

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Terameprocol
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Terameprocol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Transcription factor Sp1 (SP1) TTZEP6S SP1_HUMAN Modulator [2]
------------------------------------------------------------------------------------
Indication(s) of Aminolevulinic Acid Hydrochloride
Disease Entry ICD 11 Status REF
Actinic keratosis EK90.0 Approved [3]
Aminolevulinic Acid Hydrochloride Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Protoporphyrinogen oxidase (PPOX) TTNFMS9 PPOX_HUMAN Modulator [4]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.